Cargando…
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression
OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425376/ https://www.ncbi.nlm.nih.gov/pubmed/32571142 http://dx.doi.org/10.1177/0961203320932219 |
_version_ | 1783570482906267648 |
---|---|
author | Mahajan, Anadi Amelio, Justyna Gairy, Kerry Kaur, Gavneet Levy, Roger A Roth, David Bass, Damon |
author_facet | Mahajan, Anadi Amelio, Justyna Gairy, Kerry Kaur, Gavneet Levy, Roger A Roth, David Bass, Damon |
author_sort | Mahajan, Anadi |
collection | PubMed |
description | OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted, and 26 publications were included. RESULTS: Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. CONCLUSIONS: Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE. |
format | Online Article Text |
id | pubmed-7425376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-74253762020-09-04 Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression Mahajan, Anadi Amelio, Justyna Gairy, Kerry Kaur, Gavneet Levy, Roger A Roth, David Bass, Damon Lupus Review OBJECTIVE: The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). METHODS: A keyword-based literature search was conducted, and 26 publications were included. RESULTS: Overall, 7–31% of patients had LN at SLE diagnosis; 31–48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40–76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3–11% and 6–19%, respectively, in patients with SLE and LN. CONCLUSIONS: Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE. SAGE Publications 2020-06-22 2020-08 /pmc/articles/PMC7425376/ /pubmed/32571142 http://dx.doi.org/10.1177/0961203320932219 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Mahajan, Anadi Amelio, Justyna Gairy, Kerry Kaur, Gavneet Levy, Roger A Roth, David Bass, Damon Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title | Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title_full | Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title_fullStr | Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title_full_unstemmed | Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title_short | Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
title_sort | systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425376/ https://www.ncbi.nlm.nih.gov/pubmed/32571142 http://dx.doi.org/10.1177/0961203320932219 |
work_keys_str_mv | AT mahajananadi systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT ameliojustyna systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT gairykerry systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT kaurgavneet systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT levyrogera systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT rothdavid systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression AT bassdamon systemiclupuserythematosuslupusnephritisandendstagerenaldiseaseapragmaticreviewmappingdiseaseseverityandprogression |